DeepMed Research

The Sidney Kimmel Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.hopkinsmedicine.org/kimmel_cancer_center

Clinical Trials

Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients

Not Applicable

Recruiting

Conditions: Head and Neck Cancer
Brain Tumor

Interventions: Radiation: substructure informed planning
Diagnostic Test: MRI
Other: Neurocognitive Testing

First Posted Date: 2022-12-21

Last Posted Date: 2024-06-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 338

Registration Number: NCT05658731

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States

Renal Retention in High Grade Upper Tract Urothelial Cancer

Phase 2

Recruiting

Conditions: Bladder Cancer
Urothelial Carcinoma Bladder
High Grade Urothelial Carcinoma

Interventions: Drug: Enfortumab vedotin
Drug: Pembrolizumab

First Posted Date: 2022-12-19

Last Posted Date: 2024-12-11

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 20

Registration Number: NCT05656235

Locations: 🇺🇸
Johns Hopkins University: Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Tislelizumab
Drug: SX-682

First Posted Date: 2022-11-03

Last Posted Date: 2024-03-15

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 25

Registration Number: NCT05604560

Locations: 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

Recruiting

Conditions: Solid Tumor

Interventions: Other: Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection

First Posted Date: 2022-10-19

Last Posted Date: 2025-03-14

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 150

Registration Number: NCT05585684

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Neoadjuvant treatment

First Posted Date: 2022-10-10

Last Posted Date: 2024-03-18

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT05574712

SMART-ER: Symptom Monitoring With Patient-reported Outcomes

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Other: Semi-structured interview
Other: Outcomes4Me

First Posted Date: 2022-09-29

Last Posted Date: 2025-02-13

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 40

Registration Number: NCT05560685

Locations: 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

Post-transplant Flotetuzumab for AML

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Flotetuzumab

First Posted Date: 2022-08-18

Last Posted Date: 2024-08-20

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 3

Registration Number: NCT05506956

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer
Castration-resistant Prostate Cancer

Interventions: Drug: Olaparib
Dietary Supplement: Vitamin C

First Posted Date: 2022-08-15

Last Posted Date: 2025-01-29

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 4

Registration Number: NCT05501548

Locations: 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

Phase 2

Active, not recruiting

Conditions: Resectable Non-Small Cell Lung Cancer

Interventions: Drug: Adagrasib
Combination Product: Adagrasib/Nivolumab

First Posted Date: 2022-07-25

Last Posted Date: 2024-11-25

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 42

Registration Number: NCT05472623

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

Cardiometabolic Screening Program

Not Applicable

Recruiting

Conditions: Breast Cancer
Early-stage Breast Cancer

Interventions: Other: Prescreening
Other: Screening and Enrollment
Behavioral: Baseline
Behavioral: Interpret BMI
Other: Interpret HbA1c
Other: Interpret lipid panel and assess other risk factors
Behavioral: Assess 10 year risk of cardiovascular event
Behavioral: Recommendations
Behavioral: Follow-Up

First Posted Date: 2022-05-23

Last Posted Date: 2024-06-20

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 450

Registration Number: NCT05386719

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy